Golding H, Dimitrov D S, Manischewitz J, Broder C C, Robinson J, Fabian S, Littman D R, Lapham C K
Division of Viral Products, CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA.
J Virol. 1995 Oct;69(10):6140-8. doi: 10.1128/JVI.69.10.6140-6148.1995.
The entry of human immunodeficiency virus type 1 into cells proceeds via a fusion mechanism that is initiated by binding of the viral glycoprotein gp120-gp41 to its cellular receptor CD4. Species- and tissue-specific restrictions to viral entry suggested the participation of additional membrane components in the postbinding fusion events. In a previous study (H. Golding, J. Manischewitz, L. Vujcic, R. Blumenthal, and D. Dimitrov, J. Virol. 68:1962-1968, 1994), it was found that phorbol myristate acetate (PMA) inhibits human immunodeficiency virus type 1 envelope-mediated cell fusion by inducing down modulation of an accessory component(s) in the CD4-expressing cells. The fusion inhibition was seen in a variety of cells, including T-cell transfectants expressing engineered CD4 receptors (CD4.401 and CD4.CD8) which are not susceptible to down modulation by PMA treatment. In the current study, it was found that preincubation of A2.01.CD4.401 cells with soluble monomeric gp120 for 1 h at 37 degrees C primed them for PMA-induced down modulation (up to 70%) of the tailless CD4 receptors. The gp120-priming effect was temperature dependent, and the down modulation may have occurred via clathrin-coated pits. Importantly, nonhuman cell lines expressing tailless CD4 molecules did not down modulate their CD4 receptors under the same conditions. The gp120-dependent PMA-induced down modulation of tailless CD4 receptors could be efficiently blocked by the human monoclonal antibodies 48D and 17B, which bind with increased avidity to gp120 that was previously bound to CD4 (M. Thali, J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski, J. Virol. 67:3978-3988, 1993). These findings suggest that gp120 binding to cellular CD4 receptors induces conformational changes leading to association of the gp120-CD4 complexes with accessory transmembrane molecules that are susceptible to PMA-induced down modulation and can target the virions to clathrin-coated pits.
1型人类免疫缺陷病毒进入细胞是通过一种融合机制进行的,该机制由病毒糖蛋白gp120 - gp41与其细胞受体CD4结合引发。病毒进入存在物种和组织特异性限制,这表明在结合后融合事件中还有其他膜成分参与。在之前的一项研究(H. 戈尔丁、J. 马尼施维茨、L. 武伊契奇、R. 布卢门撒尔和D. 季米特罗夫,《病毒学杂志》68:1962 - 1968,1994年)中,发现佛波酯肉豆蔻酸乙酸酯(PMA)通过诱导表达CD4的细胞中一种辅助成分的下调来抑制1型人类免疫缺陷病毒包膜介导的细胞融合。在多种细胞中都观察到了融合抑制,包括表达工程化CD4受体(CD4.401和CD4.CD8)的T细胞转染子,这些受体不易受到PMA处理的下调影响。在当前研究中,发现将A2.01.CD4.401细胞与可溶性单体gp120在37℃预孵育1小时,可使其对PMA诱导的无尾CD4受体下调(高达70%)产生预处理作用。gp120的预处理作用依赖于温度,下调可能通过网格蛋白包被小窝发生。重要的是,表达无尾CD4分子的非人类细胞系在相同条件下不会下调其CD4受体。gp120依赖性PMA诱导的无尾CD4受体下调可被人单克隆抗体48D和17B有效阻断,这两种抗体与先前结合到CD4的gp120结合亲和力增加(M. 萨利、J. P. 摩尔、C. 弗曼、M. 查尔斯、D. D. 何、J. 罗宾逊和J. 索德罗斯基,《病毒学杂志》67:3978 - 3988,1993年)。这些发现表明,gp120与细胞CD4受体的结合会诱导构象变化,导致gp120 - CD4复合物与易受PMA诱导下调的辅助跨膜分子结合,并可将病毒粒子靶向网格蛋白包被小窝。